February 2026 Research Update

This month, one real-world pediatric study added a clearer signal that weaker bones at the start of care can travel together with a harder-to-control course in chronic nonbacterial osteomyelitis (CNO), which includes CRMO. Children who had osteoporosis on an early bone density scan were more likely to move on from first treatments like anti-inflammatory medicines and certain immune medicines to stronger second-line options. Axial involvement (bones of the spine and nearby areas) also pointed toward a higher chance of needing a treatment change. [1]

In this cohort, vitamin D deficiency was common, but it was not linked to relapse in the way the researchers measured it. The main message was not that vitamin D levels predicted flares, but that baseline bone strength and where the disease showed up in the skeleton helped sort children into groups with different chances of needing to switch treatment plans. Some details were only available for a subset who had bone density measured, which is important context when interpreting the results. [1]

For families, this study mainly adds to understanding of what early clues might suggest a more complicated CRMO/CNO path, rather than changing care right now. It supports the idea that bone density and spine-area involvement may be useful markers for future research on prognosis (how the disease may behave over time). What remains uncertain is how well these findings apply across different clinics, and whether improving bone density would change the disease course, since this study did not test that. [1]

This month reinforced that MRI is not only used to find inflammation, but also to recognize patterns that can help separate CRMO/CNO from other conditions that can look similar. Across the imaging papers, CRMO/CNO tended to show a more bone-centered pattern of inflammation, while other inflammatory diseases more often showed inflammation where tendons attach or in the joint lining. This kind of pattern-based reading can matter when symptoms overlap and the question is which condition best fits the full picture. [2]

In one ankle MRI comparison, CNO most often showed diffuse bone marrow inflammation in the heel area, while familial Mediterranean fever (FMF) more often involved tendon attachment points, and juvenile idiopathic arthritis (JIA) more often showed joint lining inflammation and tendon sheath inflammation. The CNO group was small, so the exact percentages should be viewed as an early signal, but the direction of the differences was clear in this dataset. The practical meaning is that radiologists may look not just for "is there inflammation," but also "where is it" to support the diagnosis. [2]

A separate review focused on growth-plate (physeal) changes around the knee and included chronic nonbacterial osteomyelitis as one possible cause of growth-plate disturbance. It described how routine MRI can show growth-plate problems and also discussed an advanced MRI approach that tries to measure tissue structure, which may help research into abnormal growth patterns. Because this was a review, it did not provide new patient outcome results, but it framed what radiologists look for when growth concerns are part of the story. [3]

For patients and caregivers, these papers mainly matter in the diagnosis and monitoring space rather than treatment decisions. They help explain why MRI reports may describe specific locations like the heel bone, tendon insertions, joints, or the growth plate, because those locations can point toward different diseases. What remains uncertain is how often these imaging patterns hold true across larger groups and different ages, and whether newer MRI techniques will become routinely used outside specialized centers. [2]

A single case report this month described improvement of CNO in a teenager who also had Crohn's disease after starting ustekinumab, a medicine that targets IL-12/IL-23 signaling. The main point is that, in this one person, symptoms and MRI signs of inflammation in the lower spine and sacrum improved after earlier approaches like antibiotics and surgery did not control the problem. Case reports cannot show what will happen for most people, but they can highlight treatment ideas to study more formally, especially when CRMO/CNO overlaps with inflammatory bowel disease. [4]

The report also highlighted that CNO can sometimes involve unusual spinal areas, which can lead to a long workup to rule out infection. After ustekinumab was started, the patient had substantial pain and walking improvement, and later imaging showed reduced swelling and less bone inflammation signal. The report did not present safety conclusions, and it could not answer whether the same result would occur in others without Crohn's disease. [4]

For families, this is mainly early evidence that may matter later if confirmed, not a change to standard care. It helps clarify that researchers are testing whether specific immune pathways (like IL-12/IL-23) might be relevant for some people with CNO, especially when inflammatory bowel disease is also present. What remains uncertain is who might respond, how often, and how this compares with other immune-targeting treatments, since this was only one patient. [4]